Episodios

  • Pharma Pulse: NCPA’s Medicare Negotiation Overhaul Advocacy and Norgine’s $67M UK Supply Investment

    Pharma Pulse: NCPA’s Medicare Negotiation Overhaul Advocacy and Norgine’s $67M UK Supply Investment
    Mar 9 2026
    In today's Pharma Pulse, the NCPA warns of a severe cash flow crisis for independent pharmacies under the Medicare Drug Price Negotiation Program, while Norgine commits sixty-seven million dollars to modernize its UK manufacturing hub.
    Más Menos
    1 m
  • Pharma Pulse: Eli Lilly’s Employer Connect Platform and Tandem Mobi Android Integration

    Pharma Pulse: Eli Lilly’s Employer Connect Platform and Tandem Mobi Android Integration
    Mar 6 2026

    In today’s Pharma Pulse, Eli Lilly has launched the Employer Connect platform broadening access to Zepbound for U.S. workers, while Tandem Diabetes expands the reach of its Mobi insulin pump to Android smartphones.
    Más Menos
    1 m
  • Pharma Pulse: Antengene–UCB $1.18 Billion License Agreement and AI-Driven Value Chain Efficiencies

    Pharma Pulse: Antengene–UCB $1.18 Billion License Agreement and AI-Driven Value Chain Efficiencies
    Mar 5 2026
    In today’s Pharma Pulse, Antengene and UCB ink a $1.18 billion global deal for ATG-201 to target autoimmune diseases, while AI partnerships and Pharma 4.0 technologies accelerate drug development and manufacturing efficiency.
    Más Menos
    1 m
  • Pharma Pulse: FDA Expands Pediatric Juxtapid Approval and Novo Nordisk Invests €432M in Oral GLP-1 Scaling

    Pharma Pulse: FDA Expands Pediatric Juxtapid Approval and Novo Nordisk Invests €432M in Oral GLP-1 Scaling
    Mar 4 2026
    In today's Pharma Pulse, the FDA expands the pediatric indication for Juxtapid to treat rare homozygous familial hypercholesterolemia, while Novo Nordisk announces a major €432 million investment in its Irish facility to scale global oral GLP-1 production.
    Más Menos
    2 m
  • Pharma Pulse: FDA Grants Priority Review to Rusfertide and Expands Approval for Novo Nordisk’s Sogroya

    Pharma Pulse: FDA Grants Priority Review to Rusfertide and Expands Approval for Novo Nordisk’s Sogroya
    Mar 3 2026
    In today’s Pharma Pulse, the FDA grants priority review to a therapy for polycythemia vera, while Novo Nordisk receives expanded pediatric approval for its once-weekly growth hormone.
    Más Menos
    1 m
  • Pharma Pulse: Regulatory Speed Records

    Pharma Pulse: Regulatory Speed Records
    Mar 2 2026
    In today’s Pharma Pulse, the FDA grants a lightning-fast approval for Boehringer’s lung cancer therapy under its new priority program, while CMS Administrator Mehmet Oz launches a sweeping offensive against fraudulent billing.
    Más Menos
    1 m
  • Cybersecurity and AI in the Era of Home-Based Care Logistics

    Cybersecurity and AI in the Era of Home-Based Care Logistics
    Feb 27 2026
    A conversation with Kenco’s Tim McClatchy explores how pharmaceutical logistics providers are strengthening cybersecurity across manufacturer-to-home delivery networks, deploying AI to optimize operations, and adapting to evolving regulatory pressures shaping the future of healthcare supply chains.
    Más Menos
    20 m
  • Pharma Pulse: The Oral GLP-1 Battle and GSK’s Billion-Dollar Breath of Fresh Air

    Pharma Pulse: The Oral GLP-1 Battle and GSK’s Billion-Dollar Breath of Fresh Air
    Feb 27 2026
    In today’s Pharma Pulse, Eli Lilly’s orforglipron shows superior blood sugar control over oral semaglutide, while GSK secures a $950 million acquisition of 35Pharma.
    Más Menos
    2 m